University Hospital Freiburg
uniklinik-freiburg.deTotal trials
93
Active
16
Phase 3
12
Total enrollment
103,788
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| R-MP and Procarbazine maintenance | — | — | — | — | — | 1 | |
| R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT | — | — | — | — | — | 1 |
Next readouts
- 2029-08-31
Top conditions
- Liver Cirrhosis5
- Acute Myeloid Leukemia2
- Retinopathy of Prematurity (ROP)2
- Depression2
- Non-Cirrhotic Portal Hypertension2
- Carcinoma, Hepatocellular2
- Myelodysplastic Syndromes2
- Portal Hypertension2
Frequently asked questions about University Hospital Freiburg
- How many clinical trials does University Hospital Freiburg have on ClinicalTrials.gov?
- University Hospital Freiburg is listed as the lead sponsor on 93 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Freiburg's trials are in Phase 3?
- 12 of University Hospital Freiburg's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University Hospital Freiburg focus on?
- University Hospital Freiburg's most-studied conditions on ClinicalTrials.gov are Liver Cirrhosis, Acute Myeloid Leukemia, Retinopathy of Prematurity (ROP), Depression, Non-Cirrhotic Portal Hypertension.
- When are University Hospital Freiburg's next clinical trial readouts?
- University Hospital Freiburg has 1 upcoming primary-completion readout tracked here; the soonest is “Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients”, expected around 2029-08-31.